Vox Markets Logo

Q&A with Gunsynd Executive Chairman, Hamish Harris

17 hours ago

Gunsynd has rounded off a transformational year with news of extensive additional mineralisation on the Bear-Twit project in Canada. We're joined by executive chairman Hamish Harris to talk about that, as well as uranium and the way the company's assets are positioned locally and strategically. Will there be more deals next year? Never say never, says Hamish.

  • FTSE 100 movers: Ashtead tumbles; British Land boosted by upgrade

    14 hours ago

    London's FTSE 100 was down 0.8% at 8,285.40 in afternoon trade on Tuesday.

  • FTSE 250 movers: NCC tanks; FirstGroup motors

    14 hours ago

    FTSE 250 (MCX) 20,929.78 -0.57%

  • Springfield: Equity Development

    14 hours ago

    Springfield’s H1 update reiterates current year expectations and reinforces our confidence in the medium-term outlook for the Group.

  • Begbies Traynor Group: Equity Development

    14 hours ago

    Begbies’ H1'25 revenue growth of 16%, including 11% organic growth, is testament to management’s strategy of broadening its professional service offer, increasing the group’s resilience and expansion opportunities. Having delivered a six-fold increase in Adj. PBT over the past decade, and an impressive 16% in H1'25, we see Begbies’ valuation derating as unwarranted.

IXICO wins $0.5m imaging contract for Phase 2 Huntington's Disease trial

17 hours ago

IXICO has secured a £0.5 million contract to provide imaging services for a Phase 2 Huntington's Disease clinical trial, further strengthening its position in the neurodegenerative disease research sector.

88 Energy confirms 10 hydrocarbon leads in Namibia's PEL 93 after seismic analysis

18 hours ago

88 Energy has identified 10 significant exploration leads in its 20%-owned PEL 93, Namibia, following initial interpretation of 2D seismic data, with potential for substantial hydrocarbon resources.

hVIVO secures £11.5m RSV contract with global pharma client, reaffirms 2024 guidance

21 hours ago

hVIVO has signed an £11.5m contract with an existing top-tier pharma client for an RSV human challenge trial, highlighting its expertise in accelerating infectious disease treatments. HVO also reaffirmed its FY24 revenue guidance of £62m.

Q&A with hVIVO’s Mo Khan

23 hours ago

hVIVO CEO, Yamin 'Mo' Khan announced an £11.5 million contract with an existing top-tier global pharmaceutical client to test an RSV antiviral candidate using hVIVO's Human Challenge Study Model. The Phase 2a trial is set to begin in the second half of 2025 at hVIVO's Canary Wharf quarantine facilities.

    Most Followed Companies

    In association with Vox Markets:

    Finalto
    Market commentator Neil Wilson and top guests explore the big macro themes affecting investors, economic imbalances, giant geopolitical trends, tail risks and tremors; and everywhere risks are not fully priced into markets.
    Watchlist